Company Directory - Sarepta Therapeutics, Inc.
Company Details - Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
WebsiteCambridge, United States
ISIN: US82840H1081
Sarepta Therapeutics, Inc. is a biotechnology company focused on developing precision genetic medicine for rare, infectious, and other diseases using proprietary RNA-targeted technology platforms.
CCI Score
CCI Score: Sarepta Therapeutics, Inc.
-33.87
0.01%
Latest Event
Sarepta Therapeutics PAC Expenditures
The analysis examines Sarepta Therapeutics’ use of PAC funds for contributions to federal candidates during the 2023-2024 cycle. This corporate political activity raises concerns about the influence of corporate money on democratic processes and potential indirect support for authoritarian policies.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
TOADIE
Sarepta Therapeutics, Inc. is currently rated as a Toadie.
Latest Events
- FEB062025
The analysis examines Sarepta Therapeutics’ use of PAC funds for contributions to federal candidates during the 2023-2024 cycle. This corporate political activity raises concerns about the influence of corporate money on democratic processes and potential indirect support for authoritarian policies.
-20
Political Contributions and Lobbying Efforts
March 21
Sarepta Therapeutics’ PAC expenditures, including a $18,500 contribution to federal candidates, indicate the company is engaging in political contributions which can influence public policy in ways that may inadvertently support authoritarian trends. While the amounts may be modest, the company’s decision to direct funds through PAC channels raises concerns about corporate influence in politics.
- FEB062025
Sarepta Therapeutics contributed $18,500 to federal candidates in the 2023-2024 election cycle. This political contribution raises concerns about the company's engagement in political financing and its potential complicity in fostering policies that may support authoritarian agendas.
-30
Political Contributions and Lobbying Efforts
March 21
Sarepta Therapeutics' PAC contribution of $18,500 to federal candidates indicates active involvement in political financing, which from a left-leaning perspective may contribute to the undermining of democratic processes by supporting figures who could further authoritarian policies. This financial influence is problematic given the broader context of rising authoritarianism.
Sarepta Therapeutics PAC Contributions to Federal Candidates • OpenSecrets
- JUL292024
Sarepta Therapeutics demanded that the influential Duchenne advocacy group, Parent Project Muscular Dystrophy, censor a video critical of its recently approved gene therapy, raising concerns about its manipulation of public discourse and suppression of dissent.
-50
Media Influence and Propaganda
March 21
The company’s demand to censor a video containing criticism of its gene therapy demonstrates an attempt to control the narrative and suppress dissent, aligning with practices that support authoritarian tendencies. This action is indicative of negative media influence and propaganda, wherein the company leans towards controlling information to maintain a favorable public image at the expense of transparency.
Sarepta demanded Duchenne advocacy group censor video critical of the company
- JUL292024
Sarepta Therapeutics pressured a prominent patient advocacy organization to censor a video that contained pointed criticism of its recently approved gene therapy for Duchenne muscular dystrophy. This action raises concerns about corporate influence on public discourse and the suppression of dissenting voices, aligning with authoritarian tendencies.
-60
Media Influence and Propaganda
March 21
Sarepta's demand to censor a critical video suggests an attempt to control the narrative around its gene therapy, undermining transparent debate over safety and efficacy. This behavior aligns with authoritarian methods of restricting free expression and manipulating media narratives to protect corporate interests.
- JAN012024
Sarepta Therapeutics, a biotechnology firm, was reported to have spent approximately $1,020,000 on lobbying and contributed $177,483 in the 2024 cycle. This political spending is viewed by anti-fascist perspectives as a means of influencing policy in favor of corporate interests, potentially undermining democratic processes.
-40
Political Contributions and Lobbying Efforts
March 21
The reported figures indicate that Sarepta Therapeutics engaged in significant lobbying and political contributions during the 2024 cycle. From an anti-fascist perspective, this level of spending suggests an attempt to influence policy in a way that may favor their corporate interests over public welfare, contributing to a corporate environment that can enable authoritarian practices.
- JUL012023
The FEC report indicates that Sarepta’s PAC raised a total of approximately $40,352.50 over the 2023–2024 period. While the amounts are modest, the existence and activity of a corporate PAC highlights Sarepta's involvement in political financing, a mechanism that can contribute to corporate influence in politics from an anti-fascist perspective.
-20
Political Contributions and Lobbying Efforts
March 21
The financial summary for Sarepta Therapeutics' PAC shows a collection of roughly $40,352.50 over a two-year period. Although the disclosed figure is relatively small, from an anti-fascist and left-leaning perspective, even modest corporate political contributions can reinforce the corporate influence in politics. This activity may support structures that undermine democratic accountability and potentially pave the way for policies favoring corporate interests.
SAREPTA THERAPEUTICS, INC. POLITICAL ACTION COMMITTEE (SAREPTA PAC) - committee overview
Alternatives
Pasadena, United States
0.00
Indianapolis, United States
-35.34
New York, United States
30.41
Kenilworth, United States
12.75
Kenilworth, United States
2.89
Cranbury, United States
-15.14
The Woodlands, United States
-29.63
North Chicago, United States
-31.53
Seattle, United States
-38.14
Menlo Park, United States
-49.80
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 541711
- Research and Development in Biotechnology